Drug intelligence / Profile preview

cotoretigene toliparvovec

Development stage
Discontinued
Lead developer
Biogen
Modality
Gene Therapies
Administration
Subretinal
01

Overview

Cotoretigene toliparvovec is an investigational, adeno-associated virus serotype 8 (AAV8) vector-based gene therapy designed for subretinal administration. It delivers a full-length, codon optimized retinitis pigmentosa GTPase regulator (RPGR) gene to retinal cells in patients with X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. By replacing the defective or missing RPGR gene, this therapy aims to increase levels of functional RPGR protein and potentially slow, halt, or prevent further degeneration of photoreceptors in affected individuals. Cotoretigene toliparvovec was developed primarily for XLRP and has orphan drug designation for this indication[1][2][3][4][5].

Other names
Adeno-associated viral vector serotype 8 containing the human RPGR geneAdenovirus-associated viral vector serotype 8 containing the human RPGR gene
02

Targets

RPGR (Retinitis pigmentosa GTPase regulator)

Beyond the preview

Go deeper on cotoretigene toliparvovec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cotoretigene toliparvovec.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call